- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jennifer Gass Provides an Overview of FCS' Next-Generation Sequencing Laboratory
Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation sequencing (NGS) testing in oncology care.
The state-of-the-art Florida Cancer Specialists & Research Institute (FCS) laboratory provides next-generation sequencing (NGS) testing, which helps oncologists identify genetic mutations in hundreds of different genes, all at once.
Transcript
How are things going and who is the team at the team at the new NGS laboratory that opened about a year ago at FCS?
Our pathology lab is made up of 8 different pathologist, 2 laboratory geneticist, and multiple departments. My department is the molecular department, and we are the ones that run the next generation sequencing (NGS). And within that department, we have 10 technologists and 2 variants scientists, as well as a molecular manager to support our NGS testing.
Everything is going well! we launched our first NGS test in July of 2021 and now we have brought on another test, so we support both solid tumor and hematological malignancies. And we look forward to bringing on more technologies with NGS as well as more molecular technologies.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
